The last day for trading in the warrants to 6 is today, 15 november 2023

Today, 15 November 2023, is the last day for trading in warrants of series TO 6 (the "Warrants"), which were issued in connection with ChromoGenics AB's ("ChromoGenics" or the "Company") rights issue of units announced on 17 May 2023 (the "Rights Issue"). Note that Warrants not sold by today, 15 November 2023, or alternatively exercised to subscribe for shares no later than 20 November 2023, expire without value.

In connection with the Rights Issue, ChromoGenics issued 240,222,962 Warrants. The exercise period of the Warrants started on 6 November 2023, and ends on 20 November 2023. The Company has, following the Rights Issue, carried out a reverse share split, whereby one hundred (100) shares were consolidated into one (1) share (Sw. sammanläggning 1:100). As a result of the reverse share split, the number of shares that each Warrant entitles to subscription of has been recalculated in accordance with the terms of the Warrants. One hundred (100) Warrants entails the right to subscribe for one (1) new share in the Company at a subscription price corresponding to 70 percent of the volume-weighted average price paid for the Company's share on Nasdaq First North Growth Market during a period of ten trading days ending on 31 October 2023 (including 31 October 2023), but not less than the share's quota value. The volume-weighted average price for the Company's shares during the period amounted to approximately 5.71 SEK. Therefore, the subscription price has been set at 8.51 SEK per share since the volume-weighted average price of the Company's shares during the period was below the share's quota value.

In the event that all Warrants are exercised to subscribe for shares, ChromoGenics will receive approximately SEK 20.4 million before issue costs, which are estimated to amount to approximately SEK 0.6 million.

The net proceeds of up to approximately SEK 19.8 million is intended to be used in its entirety for the go-to-market strategy, which includes increasing sales through an expanded sales organization, developing the partner concept and marketing.

Exercise of warrants of series

Application for subscription – directly-registered owners

Application takes place via an application form that is available on Vator Securities' and ChromoGenics' respective websites. Payment is made according to the instructions on the application form. Both the application form and payment must be provided to Vator Securities no later than 15.00 CET on 20 November 2023.

Application for subscription - nominee-registered owners

If the warrant holder has warrants in a depository account, investment savings account (Sw. investeringssparkonto, ISK) or capital insurance (Sw. kapitalförsäkring, KF), subscription and payment shall take place with the nominee, who will give further instructions on the procedure for exercising warrants. The warrant holder should contact its nominee in good time for further instructions regarding the exercise of warrants.

Preliminary timetable

Shares, share capital and dilution

If all Warrants are exercised, the number of shares in the Company will increase by 2,204,229 shares and the share capital by SEK 20,418,951.304458. This corresponds to a dilution effect of a maximum of approximately 36.8 percent.

Recalculation of terms for the Warrants

According to the original conditions for the Warrants, one (1) Warrant entitles, during the period 6 - 20 November 2023, to subscription of one (1) new share in ChromoGenics at an exercise price corresponding to seventy (70) percent of the volume-weighted average price paid for ChromoGenic's share on Nasdaq First North Growth Market during a period of ten trading days ending on 31 October 2023 (including 31 October 2023), but not less than the share's quota value.

Due to the reverse share split that was carried out, with record date on 12 September 2023, the conditions for the Warrants have been recalculated regarding the number of shares each Warrant entitles subscription of. The recalculation resulted in that one hundred (100) Warrants gives the right to subscribe for one (1) new share in the Company. Other conditions for the Warrants remain unchanged.

For further information, please contact:

Fredrik Fränding, CEO, ChromoGenics
Tel: +46 (0)72 249 24 62
E-mail: info@chromogenics.com

This information was submitted, through the care of the above contact person, for publication on 15 November 2023 at 08.30 CET.

About ChromoGenics

ChromoGenics is a proptech company producing smart dynamic glass that improves indoor environments and well-being and lowers buildings' energy consumption, operating expenses and impact on the climate. The company's product ConverLight® Dynamic is based on a unique patented technology from the Ångström Laboratory in Uppsala, where electrochromic coatings are sputtered onto plastic film. The result is a dynamic film that can be laminated between glass layers, which provides buildings with good solar protection and lowered environmental impact from production, transport and use. The dynamic film is easy to transport and can be applied by local partners in the glass industry, which means it is possible to avoid long-distance shipping of bulky glass. All of ChromoGenics' products strive to follow the key words environment and health. This means a focus on environmentally friendly material, lower energy consumption, increased access to daylight and views and improved indoor comfort.

The company's production facilities in Uppsala have been financed in part by a conditional loan from the Swedish Energy Agency. ChromoGenics' share (CHRO) is listed on Nasdaq First North Growth Market, and Vator is the Certified Adviser.

IMPORTANT INFORMATION

The information in this press release neither contains nor constitutes an offer to acquire, subscribe or otherwise trade in shares, warrants or other securities in ChromoGenics. The invitation to interested persons to subscribe for units consisting of shares and warrants series TO 6 in ChromoGenics has only taken place through the prospectus that ChromoGenics published on 21 June 2023. Readers are asked to read the prospectus for a description of the risks which are linked to an investment in the Company. This press release may not be published, published or distributed, directly or indirectly in or to the United States, Australia, Hong Kong, Japan, Canada, New Zealand, Switzerland, Singapore, South Africa, or any other jurisdiction where such action is wholly or partially subject to legal restrictions.